Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Agne Taraseviciute, MD, Seth M. Steinberg, PhD, Regina M. Myers, MD, Lia Gore, MD, Adam J. Lamble, MD, Patrick A. Brown, MD, Jennifer Sheppard, Bonnie Yates, NP, Perry Chung, MD, Lee Chen, Colleen Annesley, MD, Deepa Bhojwani, MD, Theodore W. Laetsch, MD, Rebecca A Gardner, MD, Susan R. Rheingold, MD, Michael A Pulsipher, MD, Nirali N. Shah, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139260

Published: 2020

Journal Articles

Reducing Dependence on General Anesthesia for Pediatric Oncology Outpatients Undergoing Repeated Lumbar Punctures

Esther R. Berko, MD, Yahui Wei, Emily Stiglich, Derek Klingman, Julie Vardaro, Sarah K Tasian, MD, Sara McDonough, CRNP, Katelyn Oranges, CRNP, Kelly Meyers, CRNP, Eileen Aber, CRNP, Miriam Kolb, CRNP, Lindsay Borel, Nicholas Evageliou, MD, Rebecca Citrin, MD, Jane Minturn, MD PhD, Anne Reilly, MD, Susan R. Rheingold, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-143153

Published: 2020

Journal Articles

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Allison Barz Leahy, MD, Kaitlin J. Stanley, MD, Regina M. Myers, MD, Amanda M. DiNofia, MD, Lisa Wray, MD, Susan R. Rheingold, MD, Colleen Callahan, CRNP, Diane Baniewicz, CRNP, Amy E. Barry, PPCNP-BC, Maria M. Patino, BS, Stephen P. Hunger, MD, Stephan Grupp, MD PhD, David M. Barrett, Shannon L. Maude, MD PhD

Blood (2019) 134 (Supplement_1): 1464.

https://doi.org/10.1182/blood-2019-130060

Published: 2019

Journal Articles

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Maureen M O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_1): 741.

https://doi.org/10.1182/blood-2019-128977

Published: 2019

Journal Articles

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)

Blood (2017) 130 (Supplement 1): 653.

https://doi.org/10.1182/blood.V130.Suppl_1.653.653

Published: 2017

Journal Articles

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 1319.

https://doi.org/10.1182/blood.V130.Suppl_1.1319.1319

Published: 2017

Journal Articles

Semi-Quantitative Analysis of CD19 and CD22 Expression in B-Lymphoblastic Leukemia and Implications for Targerted Immunotherapy

Jaclyn Rosenthal, BSN, Ammar S. Naqvi, PhD, Gerald Wertheim, MD PhD, Michele Paessler, D.O., Susan R. Rheingold, MD, Andrei Thomas-Tikhonenko, PhD, Vinodh Pillai, MD, PhD

Blood (2017) 130 (Supplement 1): 1331.

https://doi.org/10.1182/blood.V130.Suppl_1.1331.1331

Published: 2017

Journal Articles

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 217.

https://doi.org/10.1182/blood.V128.22.217.217

Published: 2016

Journal Articles

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Pamela A Shaw, PhD, Richard Aplenc, MD PhD, David M. Barrett, MD PhD, Colleen Callahan, MSN, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, J Joseph Melenhorst, PhD, Laura Motley, RN, Susan R. Rheingold, MD, David T Teachey, MD, Patricia A. Wood, MD PhD, David Porter, MD, Carl H. June, MD

Blood (2015) 126 (23): 681.

https://doi.org/10.1182/blood.V126.23.681.681

Published: 2015

Journal Articles

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Blood (2015) 126 (23): 683.

https://doi.org/10.1182/blood.V126.23.683.683

Published: 2015

Journal Articles

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

David T Teachey, MD, Simon F. Lacey, PhD BSc, Pamela A Shaw, PhD, J Joseph Melenhorst, PhD, Noelle V. Frey, MD, Shannon L Maude, MD PhD, David M. Barrett, MD PhD, Richard Aplenc, MD PhD, Fang Chen, PhD, Julie Fitzgerald, MD PhD, Vanessa Gonzalez, M.B.A, Edward Pequignot, PhD, Susan R. Rheingold, MD, Scott Weiss, MD, Jason C. White, DO, Carl H. June, MD, David L. Porter, MD, Stephan A. Grupp, MD PhD

Blood (2015) 126 (23): 1334.

https://doi.org/10.1182/blood.V126.23.1334.1334

Published: 2015

Journal Articles

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Susan R. Rheingold, MD, Lanyi Nora Chen, BS, Shannon L Maude, MD PhD, Richard Aplenc, MD PhD, Christine Barker, BS, David M. Barrett, MD PhD, Colleen Callahan, MSN, Katherine Cebry, Irina Kulikovskaya, PhD, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, Jan J. Melenhorst, PhD, Pamela A Shaw, PhD, Anna Sparrow, David T Teachey, MD, Mark Duckworth, BS, Carl H. June, MD, Stephan A. Grupp, MD PhD

Blood (2015) 126 (23): 3769.

https://doi.org/10.1182/blood.V126.23.3769.3769

Published: 2015

Journal Articles

Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment

Blood (2014) 124 (21): 2292.

https://doi.org/10.1182/blood.V124.21.2292.2292

Published: 2014

Journal Articles

The UK ALLR3 Chemotherapy Regimen for Relapsed/Refractory Acute Lymphoblastic Leukemia of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events

Weili Sun, MDPhD, Alison Marie Smith, BS, Orgal Etan, MD, Richard Sposto, PhD, Jennifer J. Wilkes, MD, Rebecca A Gardner, MD, Hur Minjun, Vanessa Pineros, Emily Olson, MD, Yijuin Tan, Susan R. Rheingold, MD, Michael J. Burke, MD, Alan S. Wayne, MD

Blood (2014) 124 (21): 3647.

https://doi.org/10.1182/blood.V124.21.3647.3647

Published: 2014

Journal Articles

Pediatric Hospital Volume and Induction Mortality in Pediatric Acute Lymphoblastic Leukemia (ALL)

Jennifer J. Wilkes, MD, Sean Hennessy, PharmD PhD, Rui Xiao, PhD, Susan R. Rheingold, MD, Alix E. Seif, MD MPH, Yuan-Shung Huang, MS, Neika Vendetti, MPH, Yimei Li, PhD, Rochelle Bagatell, MD, Richard Aplenc, MD PhD, Brian T. Fisher, DO, MSCE

Blood (2014) 124 (21): 2653.

https://doi.org/10.1182/blood.V124.21.2653.2653

Published: 2014

Journal Articles

Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433

Glen Lew, MD, Xiaomin Lu, PhD, Rochelle Yanofsky, MD FRCP(C), Susan R. Rheingold, MD, James Whitlock, Qi An, Meenakshi Devidas, PhD, Caroline A. Hastings, MD, Naomi J. Winick, MD, William L. Carroll, MD, Michael J. Borowitz, MD PhD, Stephen Hunger, MD, Michael A. Pulsipher, MD

Blood (2014) 124 (21): 684.

https://doi.org/10.1182/blood.V124.21.684.684

Published: 2014

Journal Articles

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Pamela Shaw, PhD, Richard Aplenc, MD PhD, David M. Barrett, MDPhD, Colleen Callahan, MSN, CRNP, Anne Chew, PhD, Simon F. Lacey, PhD BSc, Bruce L. Levine, PhD, J. Joseph Melenhorst, PhD, Laura Motley, RN, BSN, Susan R. Rheingold, MD, Angela Shen, MD, David T. Teachey, MD, Patricia A. Wood, MD PhD, David L Porter, MD, Carl H. June, MD

Blood (2014) 124 (21): 380.

https://doi.org/10.1182/blood.V124.21.380.380

Published: 2014

Journal Articles

L-Asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a Large Compassionate Use Protocol.

Paul V. Plourde, MD, Sima Jeha, MD, Nobuko Hijiya, MD, Frank G Keller, MD, Susan R. Rheingold, MD, Zoann E. Dreyer, MD, Gary V. Dahl, MD, Taheri Mercedes, MD, Tim Corn, MD

Blood (2012) 120 (21): 2568.

https://doi.org/10.1182/blood.V120.21.2568.2568

Published: 2012

Journal Articles

Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999–2009

Alix E. Seif, MD, MPH, Susan R. Rheingold, MD, Brian T. Fisher, DO, MSCE, Yuan-Shung V. Huang, MS, Yimei Li, PhD, Leslie S. Kersun, MD, MSCE, L. Charles Bailey, MD, PhD, Anne F. Reilly, MD, MPH, Richard Aplenc, MD, MSCE

Blood (2010) 116 (21): 3239.

https://doi.org/10.1182/blood.V116.21.3239.3239

Published: 2010

Journal Articles

A Phase I Trial of Sirolimus (Rapamycin) in Pediatric Patients with Relapsed/Refractory Leukemia.

Susan R. Rheingold, MD, Nancy Sacks, MS, RD, LDN, Yueh J. Chang, PhD, Valerie I. Brown, MD, PhD, David T. Teachey, MD, Beverly J. Lange, MD, Stephan A. Grupp, MD, PhD

Blood (2007) 110 (11): 2834.

https://doi.org/10.1182/blood.V110.11.2834.2834

Published: 2007

NARROW

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Reducing Dependence on General Anesthesia for Pediatric Oncology Outpatients Undergoing Repeated Lumbar Punctures

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Semi-Quantitative Analysis of CD19 and CD22 Expression in B-Lymphoblastic Leukemia and Implications for Targerted Immunotherapy

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment

The UK ALLR3 Chemotherapy Regimen for Relapsed/Refractory Acute Lymphoblastic Leukemia of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events

Pediatric Hospital Volume and Induction Mortality in Pediatric Acute Lymphoblastic Leukemia (ALL)

Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

L-Asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a Large Compassionate Use Protocol.

Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999–2009

A Phase I Trial of Sirolimus (Rapamycin) in Pediatric Patients with Relapsed/Refractory Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only